Clinical Trial Update: Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating continuous or intermittent cetuximab in combination with FOLFIRI as first-line therapy for patients with RAS/BRAF wild-ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Colorectal Cancer Metastatic | Phase 3 | Status: NOT_YET_RECRUITING